pH-Balanced Vaginal Gel Assessed for Dyspareunia in Breast CA Survivors

No difference versus placebo for sexual function, frequency of sexual dysfunction for breast cancer survivors
No difference versus placebo for sexual function, frequency of sexual dysfunction for breast cancer survivors

HealthDay News — For breast cancer survivors who are premenopausal at diagnosis, a pH-balanced vaginal gel is no better than placebo for improving dyspareunia and overall sexual function, according to a study published in the May issue of Obstetrics & Gynecology.

Yun Hwan Kim, MD, PhD, from Ewha Woman's University School of Medicine in Seoul, South Korea, and colleagues conducted a single-center study involving 136 breast cancer survivors who were premenopausal at diagnosis and had dyspareunia after adjuvant chemotherapy. Participants were randomized to a pH-balanced gel (69 women) or placebo (67 women) administered three times per week at bedtime and during sexual intercourse for eight weeks. 

Related Articles

The researchers found that both groups experienced a significant improvement of dyspareunia, with no difference between the groups. From baseline, the increase in median pain score was 1.2 in both groups (2.8 to 4.0 in the pH-balanced group and 3.2 to 4.4 in the placebo group; all P<0.01). There was no significant difference between the groups in the overall Female Sexual Function Index score and the frequency of sexual dysfunction, but significant improvements were noted. The pH-balanced group had slightly but significantly improved vaginal pH and vaginal maturation index. No severe adverse events were seen in either group.

"The pH-balanced vaginal gel is not superior to the placebo in improving dyspareunia and overall sexual function," the authors write.

Abstract/Full Text (subscription or payment may be required)